Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting

Journal of Chemotherapy

Volumn 8, Issue 4, 1996, Pages 315-318

  Bosnjak, S M ^a   Neskovickonstantinovic, Z B ^a   Jovanovic Micic, D J ^a   Mitrovic, L B ^a   Radulovic, S S ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

Breast cancer; Chemically induced vomiting; Ondansetron

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; KLOMETOL; METOCLOPRAMIDE; ONDANSETRON; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HEADACHE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; NAUSEA; ORAL DRUG ADMINISTRATION; VOMITING;

EID: 0029778368     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1996.8.4.315     Document Type: Article

References (14)

1. French Epirubicin Study Group. A prospective randomised phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol 1988; 6: 679-88.
2. Beck MT, Ciociola AA, Jones SE, et al. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide based chemotherapy. Ann Intern Med 1993; 118:407-13.
3. Hesketh PJ, Gandara DR. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 1991; 83: 613-20.
4. Rosso R, Campora E, Getto G, Fosser V, Marangolo M, Oliva C. Oral ondansetron (GR38032F) for the control of acute and delayed cyclophosphamide-induced emesis. Anticancer Res 1991; 11: 937-9.
5. Clavel M, Bonneterre J, D'Allens H, Paillarse JM and the French Ondansetron Study Group. Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients. Eur J Cancer 1995; 31A: 15-19.
6. Marschner NW, Adler M, Nagel GA, et al. Double blind randomized trial of antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. Eur J Cancer 1991; 27 : 1137-40.
7. Davidson NGP on behalf of the Ondansetron Study Group, Hughes LS. Oral ondansetron administered either as a single daily or twice daily dose in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy [Abstract]. Ann Oncol 1994; 5 (suppl 8): 212.
8. Blackwell CP, Harding SM. The clinical pharmacology of ondansetron. Eur J Cancer Clin Oncol 1989; 25 (Suppl 1): S21-4.
9. Grunberg SM, Groshen S, Robinson DC, Stevenson LL, Sanderson PE. Correlation of anti-emetic efficacy and plasma levels of ondansetron. Eur J Cancer 1990; 26: 879-82.
10. Dicato MA, Kaasa S, Campora E et al. Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy induced emesis: a randomized, single-blind, multicentre study. Clin Oncol 1992; 4: 275-9.
11. Jantunen IT, Muhonen TT, Kataja VV, Flander MK, Teerenhovi L. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic therapya randomised study. Eur J Cancer 1993; 29A: 1669-72.
12. Tonato M, Roila F, Del Favero A. Methodology of antiemetic trials: a review. Ann Oncol 1991; 2: 107-14.
13. Pater J, Slamet L, Zee B, Osoba D, Warr D, Rusthoven J. Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting. Support Care Cancer 1994; 2: 161-66.
14. Smith DB, Newlands ES, Rustin GJ et al. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet 1991; 338: 487-90.